Amyloid PET Burden, CSF Biomarkers, and APOE Genotype in People With Iatrogenic and Sporadic Cerebral Amyloid Angiopathy

Neurology 2026 Open access

Read full text
Authors: Benedetta Storti, Antonella Capozza, Giulia Marinoni, Camilla Strazzabosco, Mario Stanziano, Nicola Rifino, Giorgio B. Boncoraglio, Irene Scala, Michele Romoli, Andrea Paccagnella, Isabella Canavero, Luca Tagliabue
+1 more Anna Bersano
DOI: 10.1212/wnl.0000000000214949
Cited by: 1
References: 13

Abstract

BACKGROUND AND OBJECTIVES: genotype between iCAA and sporadic CAA (sCAA). METHODS: florbetaben PET scans. CSF Aβ42, Aβ40, Aβ42/Aβ40 ratio, p-tau181, and total tau (t-tau) were measured with Lumipulse assays. Multivariable regression adjusted for age and sex examined associations with Centiloid values. RESULTS: ε4 was markedly less frequent in iCAA (4.5% vs 34.2%). DISCUSSION: Patients with iCAA exhibit higher amyloid burden and a distinct biomarker profile compared with those with sCAA, supporting a divergent-possibly exogenous-mechanism of amyloid propagation. TRIAL REGISTRATION INFORMATION: SENECA, ClinicalTrials.gov Identifier: NCT04204642 (submitted on December 19, 2019).

Fields of Study & Subjects

Intracerebral and Subarachnoid Hemorrhage Research Alzheimer's disease research and treatments Amyloidosis: Diagnosis Treatment Outcomes

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
10
Pages
e214949–e214949
Publication date
5 May 2026
Language
EN